P21 vs AOD-9604
Side-by-side comparison of key properties, dosing, and research.
- Summary
- P21 is a synthetic peptide derived from CNTF (ciliary neurotrophic factor) that promotes hippocampal neurogenesis, enhances memory and spatial learning, and may reduce amyloid-beta pathology. It is used as a neurogenic and cognitive enhancer with potential anti-Alzheimer's applications.
- AOD-9604 is a modified fragment of human growth hormone (residues 177-191) with an additional tyrosine residue that significantly enhances bioavailability. Originally developed as an anti-obesity drug by Metabolic Pharmaceuticals, it stimulates lipolysis and inhibits lipogenesis without the diabetogenic effects of full GH.
- Half-Life
- Not well characterized; likely short, but neurogenic effects persist long after administration
- 30-45 minutes injectable; longer with nasal spray formulation
- Admin Route
- SubQ, Intranasal
- SubQ, Intranasal, Oral
- Research
- —
- —
- Typical Dose
- 100–500 mcg
- 300-600 mcg
- Frequency
- Once daily
- Once daily
- Key Benefits
- Promotes hippocampal neurogenesis
- Enhances spatial memory and learning
- Increases BDNF expression
- Reduces amyloid-beta plaque formation (animal models)
- Anti-tau pathology potential
- Cognitive enhancement without stimulant effects
- Potential therapeutic for Alzheimer's and cognitive aging
- Selective fat loss without anabolic side effects
- No effect on blood glucose or insulin resistance
- Improved bioavailability over Fragment 176-191
- GRAS (Generally Recognized As Safe) status in Australia
- Potential cartilage repair and anti-inflammatory properties
- Does not suppress natural GH production
- Side Effects
- Generally well tolerated in animal studies
- Limited human clinical data
- Injection site reactions
- Potential mild fatigue at initiation
- Localized injection site reactions
- Headache (rare)
- Hypoglycemia risk in combination with insulin (very rare)
- Stacks With
- —
- —